Brief: Editas Medicine Announces Strategic Transition To In Vivo Gene Editing Company

Editas Medicine

12/12/2024 22:01

Dec 12 (Reuters) - Editas Medicine Inc  EDIT.O :
    * ANNOUNCES STRATEGIC TRANSITION TO IN VIVO GENE EDITING
COMPANY
WITH INTENT TO ACHIEVE HUMAN PROOF OF CONCEPT IN APPROXIMATELY
TWO YEARS
    * INITIATING COST SAVINGS MEASURES AND REDUCTION IN
HEADCOUNT TO
ALIGN WORKFORCE
    * WILL ELIMINATE APPROXIMATELY 65% OF ITS WORKFORCE OVER
NEXT SIX
MONTHS
    * INTENDS TO SHARE PRE-CLINICAL DATA AND FURTHER DEVELOPMENT
TIMELINES FROM PROGRAMS IN Q1 OF 2025
    * JESSICA HOPFIELD, HAS BEEN NAMED CHAIR OF BOARD, EFFECTIVE
DECEMBER 31


 ((Reuters.Briefs@thomsonreuters.com;;))